bioBoyscout:
What a PR. Did I read that correctly? 97% reduction in intra-hepatic Z-AAT polymer? I keep re-opening the PR and double-checking that number - I kinda feel like I misread it the first few times. I'm guessing that the company had to PR this news, as it was material enough to bypass the wait you typically go through by reporting it at a scientific session.
With regards to commercialization, you should look no further than to James Hassard, Arrowhead's Chief Commercial Officer that was hired not that long ago. I have no doubt that he is on top of things. Here are a couple write-up on James, if you're curious as to his qualifications. I'm sure that any commercialization concerns you have will be probably put at ease after reading the following:
--------------------------
Through a 25+ year career in Sales & Marketing and Commercial Leadership, I am a "go-to" individual, for commercial challenges. My career built on expertise and executional-excellence in bio-pharmaceutical Commercial Leadership. I have been most effective in opportunities to build organizations & teams, act as a change-agent and tackle urgent challenges.
My leadership experience ranges from building commercial organizations & teams, developing teams, to re-organizing & evolving teams. My international experience & accomplishments rooted in Canada, Portugal, Switzerland and the United States, in addition to exposure to Japan, Australia and the Middle East. My functional experience across sales, marketing, market-access and general management. My Brand experience ranging from product-launch, to brand-growth through evolving & defending mature-brands.
I have a strong desire to add value to an organization, develop teams & individuals, and to continue to learn.
-------------------------
Mr. Hassard served as Senior Vice President of Marketing and Market Access at Coherus BioSciences since 2016, where he was instrumental in building the commercial organization and commercial capabilities. He co-led the launch of Coherus’ first product, a biosimilar, pegfilgrastim; one of the most successful pharmaceutical launches of 2019. Prior to his tenure at Coherus, Mr. Hassard served as Vice President of Marketing at Medivation, prior to and through its acquisition by Pfizer Pharmaceuticals. From 1999 to 2016, he held multiple increasingly senior commercial roles at Amgen, Inc., across sales and marketing, domestic and international, including an assignment as General Manager of Amgen Portugal. He was responsible for the launch, growth, and subsequent life-cycle management of several oncology and nephrology products, including darbepoetin alfa and cinacalcet. Prior to his time at Amgen, Mr. Hassard spent several years at Schering Plough Canada, in sales and marketing roles, in the therapeutic areas of oncology, cardiovascular and hepatitis. He received his Bachelor of Science in pharmacology from the University of Toronto and a master’s in business administration from Nova Southeastern University, Florida.